vs
BIOCRYST PHARMACEUTICALS INC（BCRX）与Equity Residential（EQR）财务数据对比。点击上方公司名可切换其他公司
Equity Residential的季度营收约是BIOCRYST PHARMACEUTICALS INC的1.9倍（$781.9M vs $406.6M），BIOCRYST PHARMACEUTICALS INC净利率更高（60.5% vs 48.9%，领先11.6%），BIOCRYST PHARMACEUTICALS INC同比增速更快（209.1% vs 2.0%），过去两年BIOCRYST PHARMACEUTICALS INC的营收复合增速更高（109.4% vs 3.4%）
BioCryst Pharmaceuticals是一家总部位于美国北卡罗来纳州达勒姆的制药企业，属于后期发展阶段的生物科技公司，聚焦于治疗罕见重症的口服药物研发。其研发的抗病毒药物帕拉米韦（商品名Rapivab）于2014年12月获得美国FDA批准，此后也陆续在日本、韩国与中国获批上市。
Equity Residential是总部位于美国的公开上市房地产投资信托基金（REIT），核心业务聚焦公寓类不动产投资，在全美多地持有大量优质公寓资产，深耕租赁住房市场，拥有成熟的运营管理经验和突出的行业竞争优势。
BCRX vs EQR — 直观对比
营收规模更大
EQR
是对方的1.9倍
$406.6M
营收增速更快
BCRX
高出207.1%
2.0%
净利率更高
BCRX
高出11.6%
48.9%
两年增速更快
BCRX
近两年复合增速
3.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $406.6M | $781.9M |
| 净利润 | $245.8M | $382.1M |
| 毛利率 | 97.7% | — |
| 营业利润率 | 64.0% | 50.6% |
| 净利率 | 60.5% | 48.9% |
| 营收同比 | 209.1% | 2.0% |
| 净利润同比 | 1017.5% | -8.8% |
| 每股收益（稀释后） | $1.13 | $1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCRXEQR
| Q4 25 | $406.6M | $781.9M | ||
| Q3 25 | $159.4M | $782.4M | ||
| Q2 25 | $163.4M | $768.8M | ||
| Q1 25 | $145.5M | $760.8M | ||
| Q4 24 | $131.5M | $766.8M | ||
| Q3 24 | $117.1M | $748.3M | ||
| Q2 24 | $109.3M | $734.2M | ||
| Q1 24 | $92.8M | $730.8M |
净利润BCRXEQR
| Q4 25 | $245.8M | $382.1M | ||
| Q3 25 | $12.9M | $289.1M | ||
| Q2 25 | $5.1M | $192.4M | ||
| Q1 25 | $32.0K | $256.6M | ||
| Q4 24 | $-26.8M | $419.1M | ||
| Q3 24 | $-14.0M | $143.4M | ||
| Q2 24 | $-12.7M | $177.5M | ||
| Q1 24 | $-35.4M | $295.8M |
毛利率BCRXEQR
| Q4 25 | 97.7% | — | ||
| Q3 25 | 98.6% | — | ||
| Q2 25 | 98.3% | — | ||
| Q1 25 | 96.9% | — | ||
| Q4 24 | 95.4% | — | ||
| Q3 24 | 97.3% | — | ||
| Q2 24 | 98.4% | — | ||
| Q1 24 | 98.6% | — |
营业利润率BCRXEQR
| Q4 25 | 64.0% | 50.6% | ||
| Q3 25 | 18.6% | 38.5% | ||
| Q2 25 | 18.2% | 26.6% | ||
| Q1 25 | 14.6% | 35.7% | ||
| Q4 24 | -3.4% | 57.2% | ||
| Q3 24 | 6.6% | 20.1% | ||
| Q2 24 | 8.0% | 25.3% | ||
| Q1 24 | -15.6% | 42.0% |
净利率BCRXEQR
| Q4 25 | 60.5% | 48.9% | ||
| Q3 25 | 8.1% | 36.9% | ||
| Q2 25 | 3.1% | 25.0% | ||
| Q1 25 | 0.0% | 33.7% | ||
| Q4 24 | -20.4% | 54.7% | ||
| Q3 24 | -12.0% | 19.2% | ||
| Q2 24 | -11.6% | 24.2% | ||
| Q1 24 | -38.1% | 40.5% |
每股收益（稀释后）BCRXEQR
| Q4 25 | $1.13 | $1.01 | ||
| Q3 25 | $0.06 | $0.76 | ||
| Q2 25 | $0.02 | $0.50 | ||
| Q1 25 | $0.00 | $0.67 | ||
| Q4 24 | $-0.13 | $1.10 | ||
| Q3 24 | $-0.07 | $0.38 | ||
| Q2 24 | $-0.06 | $0.47 | ||
| Q1 24 | $-0.17 | $0.77 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $274.7M | $55.9M |
| 总债务越低越好 | — | $8.2B |
| 股东权益账面价值 | $-119.2M | $11.0B |
| 总资产 | $514.2M | $20.7B |
| 负债/权益比越低杠杆越低 | — | 0.75× |
8季度趋势，按日历期对齐
现金及短期投资BCRXEQR
| Q4 25 | $274.7M | $55.9M | ||
| Q3 25 | $212.9M | $93.1M | ||
| Q2 25 | $260.0M | $31.3M | ||
| Q1 25 | $295.1M | $39.8M | ||
| Q4 24 | $320.9M | $62.3M | ||
| Q3 24 | $96.8M | $28.6M | ||
| Q2 24 | $78.4M | $38.3M | ||
| Q1 24 | $84.3M | $44.5M |
总债务BCRXEQR
| Q4 25 | — | $8.2B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $8.2B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BCRXEQR
| Q4 25 | $-119.2M | $11.0B | ||
| Q3 25 | $-387.9M | $11.1B | ||
| Q2 25 | $-421.6M | $11.0B | ||
| Q1 25 | $-451.9M | $11.0B | ||
| Q4 24 | $-475.9M | $11.0B | ||
| Q3 24 | $-468.6M | $10.9B | ||
| Q2 24 | $-475.6M | $11.0B | ||
| Q1 24 | $-476.2M | $11.1B |
总资产BCRXEQR
| Q4 25 | $514.2M | $20.7B | ||
| Q3 25 | $446.4M | $21.1B | ||
| Q2 25 | $457.2M | $21.0B | ||
| Q1 25 | $480.0M | $20.6B | ||
| Q4 24 | $490.4M | $20.8B | ||
| Q3 24 | $491.3M | $20.9B | ||
| Q2 24 | $472.4M | $19.8B | ||
| Q1 24 | $467.9M | $19.9B |
负债/权益比BCRXEQR
| Q4 25 | — | 0.75× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $292.0M | $387.0M |
| 自由现金流经营现金流 - 资本支出 | $291.2M | — |
| 自由现金流率自由现金流/营收 | 71.6% | — |
| 资本支出强度资本支出/营收 | 0.2% | — |
| 现金转化率经营现金流/净利润 | 1.19× | 1.01× |
| 过去12个月自由现金流最近4个季度 | $344.9M | — |
8季度趋势，按日历期对齐
经营现金流BCRXEQR
| Q4 25 | $292.0M | $387.0M | ||
| Q3 25 | $41.6M | $476.7M | ||
| Q2 25 | $41.3M | $359.5M | ||
| Q1 25 | $-27.5M | $425.5M | ||
| Q4 24 | $-5.2M | $354.2M | ||
| Q3 24 | $8.2M | $401.4M | ||
| Q2 24 | $-1.4M | $396.9M | ||
| Q1 24 | $-53.7M | $421.0M |
自由现金流BCRXEQR
| Q4 25 | $291.2M | — | ||
| Q3 25 | $40.3M | — | ||
| Q2 25 | $41.1M | — | ||
| Q1 25 | $-27.7M | — | ||
| Q4 24 | $-5.9M | — | ||
| Q3 24 | $8.2M | — | ||
| Q2 24 | $-1.5M | — | ||
| Q1 24 | $-53.9M | — |
自由现金流率BCRXEQR
| Q4 25 | 71.6% | — | ||
| Q3 25 | 25.3% | — | ||
| Q2 25 | 25.2% | — | ||
| Q1 25 | -19.0% | — | ||
| Q4 24 | -4.5% | — | ||
| Q3 24 | 7.0% | — | ||
| Q2 24 | -1.4% | — | ||
| Q1 24 | -58.1% | — |
资本支出强度BCRXEQR
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.3% | — |
现金转化率BCRXEQR
| Q4 25 | 1.19× | 1.01× | ||
| Q3 25 | 3.23× | 1.65× | ||
| Q2 25 | 8.12× | 1.87× | ||
| Q1 25 | -859.91× | 1.66× | ||
| Q4 24 | — | 0.85× | ||
| Q3 24 | — | 2.80× | ||
| Q2 24 | — | 2.24× | ||
| Q1 24 | — | 1.42× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
